The efficacy of immune modulators such as TNF-α inhibitors, Janus kinase (JAK) inhibitors, and IL-12/IL-23 inhibitors, which target underlying autoimmune disease activity, and the associated flares tied to PsO that occur due to molecular mimicry following infections suggest an autoimmune pathophysiology [10]. This evidence concerns the gene IL37 and autoimmune disease.